Welcome to Myr Pharma website
MYR Pharma is focused on the development of Myrcludex B, a first-in-class drug for the treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infections. Myrcludex B targets the essential hepatocyte protein NTCP and prevents the viruses from spreading in the liver. As the first drug - entry inhibitor of HBV and HDV, Myrcludex B has a landscape-changing potential in both indications.
As an inhibitor of bile acid transporter NTCP, Myrcludex B also opens up new possibilities for the treatment of a variety of inflammatory and metabolic diseases.